Cellceutix Corp. has concluded an agreement with Formatech, Inc. to formulate Kevetrin for a Phase I study. The terms of the agreement were not disclosed. Kevetrin will be presented as a lyophilized powder for reconstitution in saline solution at the time of use. The drug is being developed to treat drug resistant cancers. “This agreement allows us to stay on track for our IND filing,” said George Evans, chief executive officer of Cellceutix. “Formatech is a quality formulat...